Αρχική World News Poziotinib Shows Promise in EGFR and HER2 Exon 20 Mutated Non-Small Cell...

Poziotinib Shows Promise in EGFR and HER2 Exon 20 Mutated Non-Small Cell Lung Cancer

Patients with epidermal growth factor receptor (EGFR) exon 20 mutant metastatic non-small cell lung cancer (NSCLC) showed clinical benefit and tolerable safety following treatment with poziotinib according to findings presented at the ESMO Targeted Anticancer Therapies (TAT) Virtual Congress 2021 held on 1-2 March. Further study of poziotinib in patients with metastatic NSCLC and EGFR or HER2 exon 20 mutations showed that the safety profile could be improved by twice daily dosing.

Lead author Adrian Sacher of the Medical Oncology and Haematology Department, Princess Margaret Cancer Centre in Toronto, Canada, discussed how effective treatment of patients with metastatic NSCLC harbouring EGFR or HER2 exon 20 insertion mutations represents a critical unmet need. He explained that poziotinib, a potent, irreversible, tyrosine kinase inhibitor (TKI), has a half-life of 7.2 hours and pharmacokinetic modelling suggests that tolerability may be improved with a twice daily dosing schedule.

Therefore, poziotinib is being studied in the multi-cohort phase II ZENITH20 (NCT03318939) study and efficacy data from once daily poziotinib in treatment naïve patients as well as exploratory data from twice daily dosing were presented. The ZENITH20-Cohort 3 enrolled 79 treatment-naïve patients with metastatic NSCLC and EGFR exon 20 mutations who were treated with poziotinib at 16 mg daily, whereas the ZENITH20-Cohort 5 treated 40 patients with NSCLC and EGFR or HER2 exon 20 mutations in randomised arms of poziotinib at 10, 12, or 16 mg daily and at 6 or 8 mg twice daily.

The endpoints were objective response rate (ORR) per RECIST v1.1, duration of response (DoR), progression-free-survival (PFS) and safety.

Most of the patients demonstrated tumour reduction in ZENITH20-Cohort 3

Of the 79 patients participating in ZENITH20-3, twelve patients remained on treatment with median follow up of 9.2 months. A response was observed in 22 patients for an ORR of 27.8% (95% confidence interval [CI] 18.4–39.1%) and disease control rate was 86.1%.


ZENITH20-Cohort 3: Waterfall plot of best change from baseline in tumour volume.

© Adrian Sacher.

The median DoR was 6.5 months. Overall, 91% of patients in the intent-to-treat analysis showed tumour reduction. The median PFS was 7.2 months.

The adverse event (AE) profile was similar to that observed with second generation EGFR TKIs; ≥ grade 3 rash occurred in 33% of patients and diarrhoea in 23%.

ZENITH20-Cohort 5 showed that AEs could be reduced with twice daily dosing

Regarding the ZENITH20-Cohort 5, preliminary data from the randomised arms of daily versus twice daily dosing indicate that the rates of expected AEs was lower with twice daily dosing. The AE rates were 31% with 16 mg daily versus 21% with 8 mg twice daily dosing and 27% with 12 mg daily versus 16% with 6 mg twice daily dosing.

Data from cycle 1 showed that twice daily 8 and 6 mg dosing schedules provided a relative reduction in dose interruptions by 38% and 52%, respectively. Dr. Sacher also presented updated safety, tolerability and preliminary efficacy data during the session.


The authors concluded that these data demonstrate that poziotinib has clinically meaningful activity in treatment-naïve patients with metastatic NSCLC and EGFR exon 20 mutations at 16 mg daily dosing. Furthermore, their preliminary data suggests improved tolerability and safety with a twice daily dosing strategy that warrants further evaluation.

This study was funded by Spectrum Pharmaceuticals.


36MO – Sacher A, Le X, Cornelissen R, et al. Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer. ESMO Targeted Anticancer Therapies (TAT) Virtual Congress (1-2 March 2021).



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Puppy That Was Born Dead Becomes Therapy Dog for Cancer Patient

This story has been shared as part of the Fur Fam Story Contest. You can submit your own tale through December 5th. Voting will...

ESMO Immuno-Oncology Congress 2021, Geneva, Switzerland, 8-11 December

LUGANO, Switzerland – The ESMO Immuno-Oncology Congress 2021, the European platform dedicated to the development and use of immunotherapies for cancer treatment, will be held...

FDA Approves Sirolimus Protein-Bound Particles for Malignant Perivascular Epithelioid Cell Tumour

On 22 November 2021, the US Food and Drug Administration (FDA) approved sirolimus protein-bound particles for injectable suspension (albumin-bound) (Fyarro, Aadi Bioscience, Inc.) for...

Targeted drug recommended to treat some advanced lung cancer patients

Selpercatinib will expand treatment options available for people with RET fusion positive non small cell lung cancer. Non small cell lung cancer cells. The National Institute...

Withdrawal of Application to Change the EU Marketing Authorisation for Cervarix

The European Medicines Agency (EMA) announced on 12 November 2021 that GlaxoSmithKline Biologicals SA withdrew its application to use Cervarix (human papillomavirus vaccine ...

Robin Williams Required Film Companies He Worked With To Hire Homeless People

It’s been years since his passing, but the world still feels the loss of Robin Williams. Not only was he an extremely talented and funny...